SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is highly volatile amid escalating Middle East tensions, with initial surges driven by Strait of Hormuz disruption fears and production cuts now battling signals of de-escalation from presidential remarks and G7 discussions on strategic oil reserve releases. This has led to a polarized community debate on its immediate trajectory.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending after reporting robust Q4 earnings that significantly surpassed expectations, driven by strong sales of its rare disease drug MIPLYFFA and marking the company's achievement of profitability. This financial performance is fueling widespread community excitement, with many speculating on a potential short squeeze and re-evaluating the stock's value as a commercially successful rare disease player.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is drawing significant attention after being selected for a White House-backed eVTOL integration program to accelerate U.S. operations, alongside the launch of Uber Air in Dubai for commercial service. The community is actively debating these tangible commercialization milestones and progress towards FAA certification, even as new allegations from a competitor's lawsuit and a short report fuel further discussion.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense & National Security, Space Solutions, and Starlab Space Stations. The Defense & National Security segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Space Solutions segment consists of space infrastructure, advanced space technology, science systems and mission services. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

Voyager Technologies Inc

Voyager Technologies is trending following its recent Q4 earnings, which reported record net sales and a substantial backlog driven by its defense segment, alongside a positive 2026 outlook. The community is actively engaged in discussions around this strong performance and the transformative potential of its Starlab commercial space station as it anticipates crucial NASA contract developments.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores, Inc.

Casey's General Stores is trending as its recent earnings reports, which often highlighted strong EPS performance and consistent inside sales, spark debate about its valuation amid occasional revenue misses and slowing same-store growth in key categories. The community actively discusses its unique model, notable pizza sales, and ongoing expansion within the convenience store sector.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is drawing significant attention following its recent U.S. Department of Energy agreement for Project TEFLA, a crucial step in integral molten salt reactor fuel production, which the community sees as a catalyst for its long-term potential in powering AI data centers and positions it as an undervalued player in the advanced nuclear sector.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is trending following strong Q1 earnings that beat EPS estimates and demonstrated significant growth in its networking segment, fueled by robust AI demand and the strategic integration of Juniper Networks. The community is actively discussing HPE's positioning as an undervalued full-stack AI infrastructure player, poised to challenge competitors in both server and networking solutions.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is experiencing a massive price and volume surge as a short squeeze narrative takes hold, fueled by discussions around its recent private placement financing and updates to its lead candidate's Phase 3 trial status. Community sentiment is polarized between expectations of significant further gains and warnings of a pump-and-dump, reflecting the stock's historical volatility.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil (SCO) is trending as traders debate its tracking performance amidst extreme volatility in crude oil prices driven by geopolitical tensions. Many in the community are anticipating a significant pullback in oil from perceived overbought levels, viewing SCO as an opportunity to capitalize on an eventual decline.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is trending as investors eye a significant rebound in Chinese internet stocks, fueled by expectations of progress in US-China trade relations and China's strategic pivot towards high-tech industries and domestic stimulus. Community sentiment highlights deeply oversold technicals and compelling valuations, with notable options flow indicating strong bullish conviction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company

Livechain, Inc. (Livechain) (OTCX: LICH), a subsidiary of Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND), announced today that it has executed a debt purchase agreement with Remus Capital, a leading...

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed...

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Vyome Holdings, Inc. (Vyome) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it...

Independent Analyst Values Vyomes VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Vyome Holdings, Inc. (Vyome) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced key...

Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced its subsidiary, LiveChain, Inc. (Livechain or LICH) (OTC Markets: LICH) has executed a binding letter of intent (LOI) with Remus Capital, a...

Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds...

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

Vyome Holdings, Inc., (Vyome) (NASDAQ: HIND), a next-generation inflammation-focused company leveraging the USIndia innovation corridor, today announced its financial results and a series of...

Vyome Holdings Announces Results of Annual Shareholder Meeting

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced it held its annual shareholder meeting on October 28, 2025. All 3 Class I directors up for re-election Krishna K. Gupta, Shiladitya Sengupta, and...

Vyome Holdings, Inc. (HIND) announced on Wednesday that its VT-1908 eyedrops has been shown to significantly reduce uveitis scores in preclinical models. Shares of the company rallied 18% on Wednesday morning at the time of writing.&nbsp;Uveitis is the inflammation of a part of the eye and is implicated in approximately 30,000 new cases of legal blindness annually in the United States alone, according to Vyome. &nbsp;In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, and the efficacy of the drug was found to be similar to a clinically used steroid, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250917093826/en/Vyome-Presents-Strong-Data-Showing-Topical-VT-1908-is-an-Effective-Treatment-for-Uveitis-Opening-Up-a-%243B-Addressable-Market-Opportunity">stated</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HIND">HIND stock</a> jumped from ‘neutral’ to ‘extremely bullish territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels. Shares of the company traded as high as 70% in the pre-market session.&nbsp;According to Vyome, steroids are the first line of treatment for uveitis, but many patients do not respond to them, and they also cause major complications. “There is a huge unmet need for a topically administered drug to replace steroid use in the eye. Vyome is developing VT-1908 to address this major unmet need,” the company said while adding that the broader addressable global market to treat inflammation in the eye is expected to exceed $20 billion by 2030.“We are excited with the preclinical efficacy signals. We expect to initiate Phase 1/2 clinical trial in the second half of 2026,” CEO Venkat Nelabhotla said. While the company will initially target uveitis, the long-term goal is to replace steroids to treat ocular inflammation, he said.HIND stock is down by 98% this year and by about 99% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-its-obesity-pill-topped-novo-nordisks-oral-drug-in-late-stage-diabetes-trial/chDGpSDRd6X">Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

HIND Stock Rallies 70% Pre-Market Today – Find Out Why

In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, Vyome said. 

Equity

Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. It focuses on therapeutic solutions that target formulations for site-targeted applications. The company was founded on January 2, 2008 and is headquartered in San Clemente, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.34	--	--	N/A
Q3 '25	-$0.11	-$3.12	-2736.36%	MISSED
Q2 '25	--	-$0.07	--	N/A
Q1 '25	--	$78.08	--	N/A

HIND
Vyome Holdings Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest HIND News

HINDVyome Holdings Inc.